Electronic Nose Sensor Drift Affects Diagnostic Reliability and Accuracy of Disease-Specific Algorithms

Sofie Bosch 1,*, Renée X. de Menezes 2,3, Suzanne Pees 1, Dion J. Wintjens 4, Margien Seinen 5, Gerd Bouma 1, Johan Kuyvenhoven 6, Pieter C. F. Stokkers 5, Tim G. J. de meij 7,† and Nanne K. H. de Boer 1,†

1 Department of Gastroenterology and Hepatology, AG&M Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 Amsterdam, The Netherlands
2 Department of Epidemiology and Biostatistics, Vrije Universiteit Amsterdam, 1081 Amsterdam, The Netherlands
3 Biostatistics Unit, Netherlands Cancer Institute, 1066 Amsterdam, The Netherlands
4 Department of Gastroenterology and Hepatology, Maastricht University Medical Centre (MUMC+), 6229 Maastricht, The Netherlands
5 Department of Gastroenterology and Hepatology, OLVG West, 1061 Amsterdam, The Netherlands
6 Department of Gastroenterology and Hepatology, Spaarne Gasthuis Hospital, 2134 Hoofddorp, The Netherlands
7 Department of Pediatric Gastroenterology, UMC, Vrije Universiteit Amsterdam, 1081 Amsterdam, The Netherlands
* Correspondence: s.bosch1@amsterdamumc.nl
† These authors contributed equally to this work.

Abstract: Sensor drift is a well-known disadvantage of electronic nose (eNose) technology and may affect the accuracy of diagnostic algorithms. Correction for this phenomenon is not routinely performed. The aim of this study was to investigate the influence of eNose sensor drift on the development of a disease-specific algorithm in a real-life cohort of inflammatory bowel disease patients (IBD). In this multi-center cohort, patients undergoing colonoscopy collected a fecal sample prior to bowel lavage. Mucosal disease activity was assessed based on endoscopy. Controls underwent colonoscopy for various reasons and had no endoscopic abnormalities. Fecal eNose profiles were measured using Cyranose 320®. Fecal samples of 63 IBD patients and 63 controls were measured on four subsequent days. Sensor data displayed associations with date of measurement, which was reproducible across all samples irrespective of disease state, disease activity state, disease localization and diet of participants. Based on logistic regression, corrections for sensor drift improved accuracy to differentiate between IBD patients and controls based on the significant differences of six sensors (p = 0.004; p < 0.001; p = 0.001; p = 0.028; p < 0.001 and p = 0.005) with an accuracy of 0.68. In this clinical study, short-term sensor drift affected fecal eNose profiles more profoundly than clinical features. These outcomes emphasize the importance of sensor drift correction to improve reliability and repeatability, both within and across eNose studies.

Keywords: electronic nose; volatile organic compounds; sensor drift; inflammatory bowel disease; diagnostic

1. Introduction

Electronic nose (eNose) technology is a platform in which arrays of cross-sensitive chemical sensors are combined with pattern-based algorithms to identify gaseous mixtures [1]. These mixtures consist of volatile organic compounds (VOCs), which, when measured in (the headspace of) bodily excrements, represent end-products of human metabolism [2,3]. The VOC profile as measured by eNose is a black box in terms of metabolite composition, but its features provide a particularly suitable basis to develop diagnostic pattern-based algorithms. The advantages of this technique include fast, easy-to-perform and low-cost measurements, which underline its usability for clinical practice [4].
A well-known limitation is that sensors are prone to gradual deviations of their VOC-binding characteristics due to differences in temperature and air humidity leading to temporal sensor drift [5]. This is thought to decrease compatibility between sensor output and the developed algorithm in a later stage, which may affect accuracy during clinical studies and hampers both the comparison and validation of results when no precautions are taken [6]. Multiple studies have focused on sensor optimization to prevent drift; however, more advanced sensors are often accompanied with higher costs and more labor-intensive measurements [7,8]. Correction methods are another option to avoid bias caused by sensor drift [9–11]. For example, the recalibration of all sensors may be performed using daily study measurements for the direct correction of gas-sensor response. These methods are usually focused on composing drift in ‘baseline samples’ and extracting it from the sensor response. The most commonly proposed methods are Principal Component Analysis (PCA) or Common PCA (CPCA), Independent Component Analysis (ICA) and Discrete Wavelet Transform (DWT) [12–17]. This is, however, time-consuming, and a large batch of ‘baseline’ samples are needed, which are often of limited availability. Another method by which to correct for drift is by identifying components unrelated to classification, including proposed methods such as Orthogonal Signal Correction (OSC), Linear Discriminant Correction (LDA) and Partial Least Squares (PLS) [18–21]. A third way to correct for sensor drift is more universally applicable and involves machine learning such as Kernel Transformation (DCKT), Self-Organizing Maps (SOMs), Adaptive Resonance Theory (ART), and Deep-learning Neural Networks [9,11,22–27]. The choice of the optimal fitting correction method is dependent on both the characteristics of the data and the type of sensors used.

Electronic nose technology has been presented as a promising non-invasive tool to detect various diseases (e.g., lung cancer, colorectal cancer, celiac disease) [28–30]. Nevertheless, the use of correction methods for sensor drift is not yet standardized in clinical studies. Short-term sensor drift may affect the accuracy of algorithms as early as during data training. As this drift occurs within the ‘black box’, its possible effect modification may go unnoticed. The aim of this study was to investigate the influence of eNose sensor drift on the development of a disease-specific diagnostic algorithm in a real-life cohort. In addition, we proposed a method to correct for this drift. This is illustrated by means of a study on the fecal VOC profiles of patients with inflammatory bowel disease (IBD), as multiple previous studies have identified the eNose-captured VOC profile as a potential diagnostic biomarker [31–35].

2. Materials and Methods

2.1. Study Design

This multi-center cohort study was performed between April 2016 and May 2018 at the Department of Gastroenterology and Hepatology of one tertiary hospital (Amsterdam UMC, location VUmc) and two district hospitals (Spaarne Gasthuis, Haarlem and Hoofddorp and OLVG West, Amsterdam), all located in the Netherlands. Approval of this study was provided by the Medical Ethical Review Committee (METc) of the Amsterdam UMC under file number 2016.135 and by the local medical ethical committees of the participating centers. All participants provided written informed consent before inclusion in this study.

2.2. Participants

2.2.1. Inflammatory Bowel Disease

Patients with an established diagnosis of IBD, aged 18 years and above, and with a scheduled endoscopy were asked to participate in this study irrespective of their endoscopy indication. Patients were excluded in the case of diagnosis with IBD-unclassified (IBD-U) and co-existing abnormalities during endoscopy (e.g., colorectal cancer, polyps, diverticulitis) with the exception of hemorrhoids and diverticula. Other exclusion criteria were history of bowel cancer, failure to perform a complete colonoscopy (independent of the reason), absence of sufficient endoscopy images to evaluate activity of IBD or insufficient fecal sample mass collected to perform a VOC analysis.
2.2.2. Controls

All patients aged 18 years and above with a scheduled colonoscopy at the Amsterdam UMC, OLVG West or Spaarne Gasthuis facilities were asked to participate in this study regardless of the indication for endoscopy. Patients were eligible to participate in this study if no mucosal abnormalities were observed during colonoscopy (with the exception of hemorrhoids and diverticula). In cases where mucosal biopsies were taken, histologic reports were evaluated and subjects were excluded if histologic abnormalities were described by the pathologist. Other exclusion criteria were a history of bowel diseases (except appendicitis), failure to perform a complete colonoscopy (independent of the reason) and/or the collection of insufficient fecal sample mass to perform the VOC analysis.

2.3. Data Collection

2.3.1. Sample Collection

All participants collected a fecal sample in a stool container (Stuhlgefäß 10 mL, Frickenhausen, Germany) prior to colonic lavage and stored these samples in their freezer at home within one hour following collection. On the day of their colonoscopy, participants transported the sample to the hospital in a cooled condition using ice packs. Upon arrival at the hospital, fecal samples were directly stored in the freezer at \(-24^\circ\text{C}\).

2.3.2. Assessment of Variables

All participants completed a questionnaire with items on age, gender, body-mass index (BMI), smoking habits, dietary habits, medical history, comorbidity and use of medication. The IBD patients were matched to controls in a 1:1 ratio, based on age, gender and smoking status as we previously observed that these variables influence fecal VOC profiles [36]. In addition, they were matched according to hospital of inclusion to avoid any possible effects of sample storage on VOC profiles. From the IBD patients, additional disease-specific characteristics were obtained to rule out influence of these variables on sensor output. Data on disease localization and behavior based on the Montreal scores were extracted from the electronic patient records [37]. Information on disease activity at sample collection was obtained by asking two independent gastroenterology consultants to score the endoscopic images. To avoid inter-individual variation in scoring, one of the specialists was present for every assessment. All IBD endoscopy procedures were scored according to the Van der Heide classification, a generic grading system focusing on a broad range of mucosal characteristics [38]. In addition, the mucosal appearance of ulcerative colitis (UC) patients was scored using the Mayo classification (remission defined as 0, mild to severe activity scored as \(\geq 1\)) [39]. Rutgeert’s Postoperative Endoscopic Index with scores between \(i0\) (no lesions) and \(i4\) (diffuse inflammation) was used to describe Crohn’s disease (CD) patients with an ileocolic resection [40]. Remission was defined as a Rutgeert’s classification of \(\leq i1\) and active disease as \(\geq i2\). The remaining CD patients were categorized into remission and active disease categories based on the opinion of the two consultants.

2.4. Sample Preparation

From each original collected fecal sample, 500 mg (with a deviation of 5%) was weighted on a calibrated scale (Mettler Toledo, AT 261 Delta Range, Columbus, OH, USA). This sample amount was chosen based on results of a previous sampling method study for VOC-pattern recognition using field asymmetric ion mobility spectrometry (FAIMS), showing that samples of 500 mg provide an optimum ratio of VOCs to the headspace to distinguish the scent profiles of IBD patients [41]. The subsample was then transferred into a labelled 3 mL sealed vacutainer (BD vacutainer, Franklin Lakes, NJ, USA) and stored once again in a \(-24^\circ\text{C}\) freezer. Fecal samples were thawed to room temperature (18 °C) 30 min prior to analysis to allow VOCs to fill the headspace.
2.5. Electronic Nose Device

Fecal VOCs were analyzed using an eNose device (Cyranose 320®, Smiths Detections, Pasadena, CA, USA). This apparatus operates on an array of 32 nanocomposite sensors. Each sensor consists of carbon nanotubes, conducting polymers and metallic and non-metallic nanoparticles that interact specifically with VOCs in the sample. Interaction between specific sensors and VOCs results in unique changes of electrical resistance, which are calculated per sensor using the following formula:

\[
\frac{\Delta R}{R_0}
\]

where \(\Delta R\) denotes the maximum resistance change of the sensor during each measurement and \(R_0\) is the baseline resistance before the start of the measurement. As there are 32 sensors in this particular eNose, this leads to 32 unique signals per sample, combined as the so-called ‘smell-print’. As shown in this formula, the baseline resistance has a major influence on sensor output, meaning that temporal sensor drift during sample measurements has an influence on the ‘smell-prints’.

2.6. Fecal Volatile Organic Compound Analysis

The VOC measurements were performed on four subsequent days. All samples were measured in random order by a blinded analyst. Analyses were performed using a previously validated standard operating procedure [42]. In Supplementary Figure S1, a schematic setup of eNose measurements is presented. In short, the vacutainer is connected to the air-tight loop system of the Cyranose 320® tool by piercing two needles (BD Blunt fill needle 1.2 × 40 mm, Franklin Lakes, NJ, USA) into the cap of the vacutainer. These needles are attached to two oxygen hoses (Argyle Covidien tube 3 mm, Mansfield, MA, USA), which are connected to the snout and outlet of the Cyranose 320® tool by three-way valves (stopcock connecta plus, McFarlane Medical, Melbourne, Australia). The valves provide control of the airflow direction. A water filter (Nalgene 25 mm Syringe Filter, Thermo Scientific, Waltham, MA, USA) is connected between the needle and the oxygen hose to prevent condensation in the system and thus contamination. Before the actual VOC analysis is performed, sensors are purged for 90 s with filtered ambient air (VOC filter A1, North Safety, Middelburg, The Netherlands) to detach residual VOCs from the eNose sensors. Then, a baseline measurement using ambient filtered air takes place for 30 s. Subsequently, the actual measurement is performed for 60 s, followed by purging of the inlet for 15 s and purging of the sensors for 90 s, to remove the VOCs from the sensors for the next analysis. After each sample analysis, the needles, tubes, connectors and three-way valves are replaced to prevent contamination.

2.7. Statistical Analyses

All raw sensor output data, including our R script and output, are openly available at the following link: https://doi.org/10.6084/m9.figshare.21547794.v1 (accessed on 18 November 2022). Demographic data were described and compared using IMB SPSS statistics version 25. Levene’s test was used to assess the assumption of equal variances; subsequently, one-way ANOVA or Kruskal–Wallis tests were used to compute differences in baseline demographics between the control groups and the following two phenotypes of IBD: Crohn’s disease (CD) and ulcerative colitis (UC). Data from the eNose were analyzed using R. Spearman’s correlation was used to assess association between sensor outcomes when exposed to fecal samples. Then, heatmaps of the sensor output were obtained using scaled outcomes per sensor by first computing the mean and standard deviation per sensor across all samples, followed by subtracting each measurement from the mean and dividing it by its standard deviation, so that all sensor measurements are on the same scale across all sensors. Then, the characteristics of samples were added to the heatmap, including the date of the analysis. The eNose data displayed an association with the date of measurement which was reproducible across samples. We proposed the use of a correction factor for the
date of sample measurement based on the assumption of Component Correlation (CC), in which it is assumed that all sensors behave in a similar way with respect to drift and the vector of drift [10]. We fitted a regression model based on the control samples to correct for the date of measurement for all samples. Briefly, the mean relative sensor deviation per day was calculated per sensor for all control samples and sensor outcome for cases were corrected based on these data. The residuals of this model applied to the patient data then yield date-corrected measurements, which were used for subsequent analysis. Differences in sensor outcome between groups were then calculated and a logistic regression analysis was performed on the sensors which differed significantly between groups. When significant differences were found, leave-one-out cross-validation was performed using optimum cut-off values, and a prediction model was constructed.

3. Results
3.1. Baseline Characteristics

Baseline demographics of study participants and endoscopy indication are described in Table 1. A total of 63 IBD patients were included. Of these, 24 were CD patients (19 active disease, 5 remission) and 39 were UC patients (22 active disease, 17 remission). Out of the 227 included controls, a total of 63 were strictly matched to IBD patients based on age, gender, smoking status and hospital of inclusion. Information on Montreal classification, disease activity and medication use of IBD patients is provided in Supplemental Tables S1–S3.

Table 1. Baseline characteristics.

|                         | Controls ($n = 63$) | Inflammatory Bowel Disease ($n = 63$) |
|-------------------------|--------------------|---------------------------------------|
|                         | Crohn’s disease ($n = 24$) | Ulcerative colitis ($n = 39$) | Total IBD ($n = 63$) |
| Sex, ♀ ($n, %$)         | 39 (61.9)           | 15 (62.5)                             | 24 (61.5)               | 39 (61.5)         |
| Age, mean ± SD          | 56.2 ± 11.1         | 34.2 ± 25.7                           | 50.5 ± 17.6             | 44.3 ± 22.3       |
| Smoking ($n, %$)        |                    |                                       |                         |                  |
| Current                 | 8 (12.7)            | 6 (25.0)                              | 2 (5.1)                 | 8 (12.7)          |
| Past                    | 22 (34.9)           | 8 (33.3)                              | 14 (35.9)               | 22 (34.9)         |
| Never                   | 33 (52.4)           | 10 (41.7)                             | 23 (59.0)               | 33 (52.4)         |
| Disease activity ($n, %$) |                  |                                       |                         |                  |
| Quiescent               | N.A.                | 5 (20.8)                              | 17 (43.6)               | 22 (34.9)         |
| Active                  | N.A.                | 19 (79.2)                             | 22 (56.4)               | 41 (65.1)         |
| Diet ($n, %$)           |                    |                                       |                         |                  |
| None                    | 53 (84.1)           | 18 (75.0)                             | 33 (84.6)               | 51 (81.0)         |
| Vegetarian              | 2 (3.2)             | 1 (4.2)                               | 0 (0)                   | 1 (1.6)           |
| Gluten-free             | 3 (4.8)             | 2 (8.3)                               | 3 (7.7)                 | 5 (7.9)           |
| Lactose-free            | 2 (3.2)             | 1 (4.2)                               | 0 (0)                   | 1 (1.6)           |
| Other                   | 5 (7.9)             | 2 (8.3)                               | 3 (7.7)                 | 5 (7.9)           |
| Indication for endoscopy * ($n, %$) |              |                                       |                         |                  |
| Positive FIT test       | 5 (7.9)             | 0 (0)                                 | 2 (5.1)                 | 2 (3.2)           |
| Rectal blood loss       | 8 (12.7)            | 3 (12.5)                              | 3 (7.7)                 | 6 (9.5)           |
| Change in bowel habits  | 10 (15.9)           | 0 (0)                                 | 0 (0)                   | 0 (0)             |
| Surveillance †          | 14 (22.2)           | 0 (0)                                 | 20 (51.3)               | 20 (31.7)         |
### Table 1. Cont.

| Controls | Inflammatory Bowel Disease |
|----------|----------------------------|
| **Indication for endoscopy** *(n, %)* | | |
| Abdominal pain | 13 (20.6) | 3 (12.5) | 0 (0) | 3 (4.8) |
| Diarrhea | 5 (7.9) | 1 (4.2) | 0 (0) | 1 (1.6) |
| Family history of CRC | 4 (6.3) | 0 (0) | 0 (0) | 0 (0) |
| Follow-up after diverticulitis | 2 (3.2) | 0 (0) | 0 (0) | 0 (0) |
| Weight loss | 3 (4.8) | 0 (0) | 0 (0) | 0 (0) |
| Constipation | 3 (4.8) | 0 (0) | 0 (0) | 0 (0) |
| Anemia | 1 (1.6) | 0 (0) | 0 (0) | 0 (0) |
| Disease monitoring | N.A. | 6 (25) | 0 (0) | 6 (9.5) |
| Suspected exacerbation | N.A. | 10 (41.7) | 12 (30.8) | 22 (34.9) |
| Other ** | N.A. | 3 (12.5) | 0 (0) | 3 (4.8) |

Abbreviations: *n*, number; SD, standard deviation; CD, Crohn’s Disease; UC, Ulcerative Colitis; IBD, Inflammatory Bowel Disease; NA, not applicable. * For seven controls and two CD patients, multiple indications were noted; for two UC patients, indication was insufficiently reported † Surveillance after CRC, for polyps and Lynch taken together ** other reasons for endoscopy in CD patients were medication adjustments (*n* = 1), monitoring pre-fistula surgery (*n* = 1) and monitoring after ileocecal resection (*n* = 1).

#### 3.2. The Effects of Sensor Drift on Fecal Volatile Organic Compound Profiles

Based on Spearman’s correlation coefficient, it was revealed that sensor outcomes were moderately to highly correlated for all but three sensors, specifically numbers 6, 19 and 24 (Figure 1). 

![Figure 1](image.png)  
Figure 1. Association between sensors. Spearman correlation of sensors. Sensors are depicted on both the X-axis and Y-axis. A strong positive correlation is seen amongst the majority of sensors.

A sensor output heatmap is depicted in Figure 2. There was a clear separation between samples measured on the first two dates and samples measured on the second two dates, irrespective of their disease state, disease activity state, disease localization and diet of...
participants. We observed that all sensor outcomes were on or below their average outcome across samples for the first two days of measurements and on or above for the second two days of measurements. Additional principle component analysis (PCA) charts present the distribution of sensor data based on date of measurement. These PCA charts are included in the R output file, which is openly available at the following link: https://doi.org/10.6084/m9.figshare.21547794.v1 (accessed on 18 November 2022).

![Figure 1](image1.png)

**Figure 1.** Association between sensors. Spearman correlation of sensors. Sensors are depicted on both the X-axis and Y-axis. A strong positive correlation is seen amongst the majority of sensors.

![Figure 2](image2.png)

**Figure 2.** Scaled heatmap of sensor output before correction for date of measurement. The mean and standard deviation per sensor across all samples were calculated. Then, each sample measurement was subtracted from the mean sensor outcome and divided by its standard deviation. This was performed across all sensors and samples so that all sensor measurements were on the same scale. Samples are depicted on the Y-axis, while sensors are depicted on the X-axis. Colored strips on the Y-axis depict the distribution of sample characteristics amongst the samples. (A) Distribution of CD, UC and controls. (B) Distribution of active disease or remission; control samples are depicted as separate group. (C) Distribution of diet including no diet, vegetarian diet, gluten-free diet, lactose-free diet and non-specified diets. (D) Distribution of abdominal surgical history except appendectomy, including no abdominal surgery, ileocecal surgery and colectomy; control samples are depicted as separate group. (E) Distribution of measurement date.

As mentioned in the Materials and Methods section, a correction for sensor output was calculated based on control samples using logistic regression. A scaled heatmap after sensor correction was constructed and is depicted in Figure 3. We observed an improved distribution of the measurement date across all samples. In the online available R output file, additional PCA charts present the distribution of sensor output based on date of analysis prior to and after correction for date of measurement (https://doi.org/10.6084/m9.figshare.21547794.v1, accessed on 18 November 2022).
Figure 3. Scaled heatmap of sensor output after correction for date of measurement. Scaled heatmaps of the sensor output. Date of sample measurement was found a confounding factor. Therefore, a correction was applied for date of measurement for all sensor outcomes. Then, the mean and standard deviation per sensor across all samples were calculated. Each sample measurement was subtracted from the mean sensor outcome and divided by its standard deviation. This was across all sensors and samples so that all sensor measurements were on the same scale. Samples are depicted on the Y-axis, while sensors are depicted on the X-axis. Colored strips on the Y-axis depict the distribution of sample characteristics amongst the samples. (A) Distribution of measurement date. (B) Distribution of CD, UC patients and controls. The six discriminating sensors are indicated by the p-values for the discrimination between IBD and controls.

3.3. Differentiation between Inflammatory Bowel Disease and Controls

Prior to data correction, no significant differences were seen between fecal VOC profiles of IBD patients and controls. Based on the corrected data, fecal VOC profiles differed between IBD patients and controls based on a total of six sensors (p = 0.004; p < 0.001; p = 0.001; p = 0.028; p < 0.001 and p = 0.005). Sensor specifications with corresponding p-values are depicted in Figure 3. Based on the significant sensors, a logistic regression analysis and subsequently leave-one-out cross-validation were performed. The resulting prediction model for IBD patients versus controls is provided in Figure 4. Using an optimal cut-off value of 0.6, the total accuracy was 0.68 with a sensitivity of 0.78 and specificity of 0.59. The positive and negative predictive value (PPV and NPV) were 0.65 and 0.73, respectively. The prediction error distribution was similar for IBD and healthy controls, reflecting the equal group sizes. The Brier score, depicting the mean squared prediction error independent of a cut-off, was 0.2. Box plots of prediction errors are depicted in Supplementary Figure S2.
The aim of the current study was to present the effects of sensor drift on a real-life cohort. As presented in previous studies, combined with its low costs and fast measurements, eNose devices are usually small and may easily be transported from patient to patient, underlining its practicality for in-hospital use. Different approaches for the correction of drift have been proposed; however, this form of correction is not yet routinely used. Most correction methods for sensor drift are reported once and are mostly based on available, public and mostly artificial online environments. The aim of the current study was to present the effects of sensor drift on a real-life cohort.

In the current study, a thorough assessment of patient characteristics was carried out by collecting information on age, gender, BMI, smoking habits, diet, disease localization, behavior and disease activity derived by endoscopy, which is the gold standard. By doing so, we were able to demonstrate that sensor drift has a major influence on ‘smell-prints’, regardless of the participant-specific variables. In addition, a standardized protocol for sample storage conditions and measurements was used, which was based on previous research and minimized variations in sampling conditions [41,42]. Nonetheless, this study also has some limitations. First, patients collected the fecal samples in a non-regulated environment.

In the current study, however, a worrisome effect of short-term sensor drift was observed. Multiple factors may have contributed to this drift. Even though the standard operating procedure was identical for all measurements, the flow from the airvalve may have varied throughout measurements. This may consequently have led to differences in gas dispersion and total gasflow at specific sensors over time. In addition, when connecting the fecal sample to the eNose setup, exposure of the fecal VOC headspace to the environment cannot be avoided for a brief period of time. Therefore, environmental variations such as ambient air humidity, temperature and contamination with laborant specific odors may have affected the VOC composition when connecting the sample to the eNose setup.

Although sensor drift is a limitation of eNose technology, its high diagnostic accuracy presented in previous studies, combined with its low costs and fast measurements, is appealing for routine testing in clinics [4]. In addition, eNose devices are usually small and may easily be transported from patient to patient, underlining its practicality for in-hospital use. Different approaches for the correction of drift have been proposed; however, this form of correction is not yet routinely used. Most correction methods for sensor drift are reported once and are mostly based on available, public and mostly artificial online environments. The aim of the current study was to present the effects of sensor drift on a real-life cohort.

In the present study, we have demonstrated that short-term eNose sensor drift affects fecal VOC profiles throughout the measurements of a real-life clinical study and subsequently influences its diagnostic potential. Though both result in lower diagnostic potential, long-term sensor drift caused by surface aging and sensor poisoning, for example, has been described to have a greater effect on sensor outcomes compared to short-term drift in the available literature [6]. In the current study, however, a worrisome effect of short-term sensor drift was observed.

Figure 4. Prediction of inflammatory bowel disease based on leave-one-out cross-validation. Dashed line indicates a cut-off value of 0.6. Y-axis depicts the predicted probabilities of being healthy (so no IBD) for all samples. On the X-axis, the samples are depicted, sorted by predicted probability of IBD, represented by triangles. Dots indicate the known sample classification (healthy control, at y = 1 and blue; IBD, at y = 0 and red).
setting, which means that contamination with VOCs from the environment cannot be ruled out. Second, although we attempted to correct for sensor drift, our current study protocol does not include standardized data collection of ‘blank’ samples containing only filtered air between sets of study samples. Therefore, our correction factors were calculated using the control group in which, although small, differences in fecal VOC profiles are expected. This may have influenced the final corrected outcomes to some extent. Third, it should be noted that, although each sensor of the Cyranose 320® tool is thought to have a distinct change in electrical resistance upon contact with a volatile organic compound mixture, most sensor outcomes were correlated in the current study. This suggests that these polymer sensors have a common rather than specific reaction to fecal samples.

For future studies aiming to use eNose technology, we strongly recommend including correction for temporal sensor drift in the standard operating procedure. Researchers should assess the effects of sensor drift on the measurements per study separately, as the extent may vary depending on the eNose used and the moment of measurements. This should be performed in a standardized manner depending on the input characteristics and sensor type. In addition, to avoid inaccurate results with the diagnostic algorithm, we strongly recommend spreading case and control samples evenly throughout the days of measurements.

5. Conclusions

In conclusion, short-term eNose sensor drift affects VOC profiles as early as during study measurements, affecting diagnostic accuracy when performing clinical trials. Raising awareness on this topic amongst clinicians is important as correction for this variation improves the reliability and repeatability of eNose study outcomes.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/s22239246/s1. Supplementary Figure S1: A schematic image of the electronic nose set-up. Supplementary Figure S2: Box plots of prediction errors. Supplementary Table S1: Disease behaviour and localisation of patients with inflammatory bowel disease. Supplementary Table S2: Endoscopic assessment of patients with inflammatory bowel disease. Supplementary Table S3: Medication use at time of sample collection per disease activity subgroup. Supplementary Figures S1 and S2 and Supplementary Tables S1–S3 have been published online only. The raw sensor data, R script and output files are accessible via the link below, and supplemental data are provided. https://doi.org/10.6084/m9.figshare.21547794.v1 (accessed on 18 November 2022).

Author Contributions: Conceptualization S.B., T.G.J.d.M. and N.K.H.d.B.; methodology, S.B., T.G.J.d.M., N.K.H.d.B. and R.X.d.M.; software, T.G.J.d.M., N.K.H.d.B. and R.X.d.M.; validation R.X.d.M.; formal analysis R.X.d.M.; investigation, S.B., S.P., D.J.W., P.C.F.S., J.K. and M.S.; resources, N.K.H.d.B. and T.G.J.d.M.; data curation, S.B., S.P. and D.J.W.; writing—original draft preparation, S.B.; writing—review and editing, all; visualization, R.X.d.M.; supervision, G.B., N.K.H.d.B. and T.G.J.d.M.; project administration, S.B.; funding acquisition, N.K.H.d.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received an unrestricted grant from TAKEDA.

Institutional Review Board Statement: The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki (6th revision, 2008) as reflected in the a priori approval by the Medical Ethical Review Committee (METc) of the Amsterdam UMC, location VUMc under file number 2016.135, by the METc of the MUMC+ under file number NL24572.018.08, and by the local medical ethical committee of the OLVG West and Spaarne Gasthuis.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Anonymized raw sensor output data as well as the statistical R script and output are openly accessible via the following link: https://doi.org/10.6084/m9.figshare.21547794.v1 (accessed on 18 November 2022).
Conflicts of Interest: S Bosch has nothing to declare. R Menezes has nothing to declare. S Pees has nothing to declare. D Wintjens has nothing to declare. M Seinen has nothing to declare. G Bouma has nothing to declare. P Stokkers has nothing to declare. J Kuijvenhoven has served as a consultant for Janssen Pharmaceuticals. TGJ de Meij has served as a speaker for Mead Johnson. He has received a (unrestricted) research grant from Danone. NHK de Boer has served as a speaker for AbbVie and MSD. He has served as consultant and principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted) research grant from Falk, MLDS and Takeda.

References
1. Gardner, J.W.; Bartlett, P.N. A brief history of electronic noses. *Sens. Actuators B Chem.* 1994, 18, 210–211. [CrossRef]
2. Garner, C.E.; Smith, S.; de Lacy Costello, B.; White, P.; Spencer, R.; Probert, C.S.; Ratcliffe, N.M. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. *FASEB J.* 2007, 21, 1675–1688. [CrossRef] [PubMed]
3. Pleil, J.D.; Lindstrom, A.B. Exhaled human breath measurement method for assessing exposure to halogenated volatile organic compounds. *Clin. Chem.* 1997, 43, 723–730. [CrossRef]
4. Covington, J.A.; van der Schee, M.P.; Edge, A.S.; Boyle, B.; Savage, R.S.; Arasaradnam, R.P. The application of FAIMS gas analysis in medical diagnostics. *Analyt 2015*, 140, 6775–6781. [CrossRef]
5. Liu, T.; Li, D.; Chen, J.; Chen, Y.; Yang, T.; Cao, J. Gas-Sensor Drift Counteraction with Adaptive Active Learning for an Electronic Nose. *Sens. Actuators B Chem.* 2018, 18, 4028. [CrossRef] [PubMed]
6. Dennler, N. Drift in a popular metal oxide sensor dataset for gas classification limitations. *Sens. Actuators B Chem.* 2022, 361, 131668. [CrossRef]
7. Kulkarni, G.S.; Zang, W.; Zhong, Z. Nanoelectronic Heterodyne Sensor: A New Electronic Sensing Paradigm. *Acc. Chem. Res.* 2016, 49, 2578–2586. [CrossRef] [PubMed]
8. Kanu, A.B.; Hill, H.H., Jr. Ion mobility spectrometry detection for gas chromatography. *J. Chromatogr. A* 2008, 1177, 12–27. [CrossRef]
9. Liu, T.; Li, D.; Chen, J.; Chen, Y.; Yang, T.; Cao, J. Active Learning on Dynamic Clustering for Drift Compensation in an Electronic Nose System. *Sensors 2019*, 19, 3601. [CrossRef]
10. Rudnitskaya, A. Calibration Update and Drift Correction for Electronic Noses and Tongues. *Front. Chem.* 2018, 6, 433. [CrossRef] [PubMed]
11. Tao, Y.; Xu, J.; Liang, Z.; Xiong, L.; Yang, H. Domain Correction Based on Kernel Transformation for Drift Compensation in the E-Nose System. *Sensors 2018*, 18, 3209. [CrossRef]
12. Ziyatdinov, A.; Marco, S.; Chaudry, A.; Persaud, K.; Caminal, P.; Perera, A. Drift compensation of gas sensor array data by common principal component analysis. *Sens. Actuators B Chem.* 2010, 146, 460–465. [CrossRef]
13. Artursson, T.; Eklov, T.; Lundstrom, I.; Martensson, P.; Sjostrom, M.; Holmberg, M. Drift correction for gas sensors using multivariate methods. *J. Chemometrics* 2000, 14, 711–723. [CrossRef]
14. Natale, C.D.; Davide, F.A.M.; D’Amico, A. A self-organizing system for pattern classification: Time varying statistics and sensor drift effects. *Sens. Actuators B Chem.* 1995, 27, 237–241. [CrossRef]
15. Kermit, M.; Tomic, O. Independent component analysis applied on gas sensor array measurement data. *IEEE Sens. J.* 2003, 3, 218-228. [CrossRef]
16. Mallat, S.G. A theory for multiresolution signal decomposition: The wavelet representation. *IEEE Trans. Pattern Anal. Mach. Intell.* 1989, 11, 674–693. [CrossRef]
17. Zuppa, M.; Distante, C.; Persaud, K.C.; Siciliano, P. Recovery of drifting sensor responses by means of DWT analysis. *Sens. Actuators B Chem.* 2007, 120, 411–416. [CrossRef]
18. Padilla, M.; Perera, A.; Montoliu, I.; Chaudry, A.; Persaud, K.; Marco, S. Drift compensation of gas sensor array data by Orthogonal Signal Correction. *Chemom. Intell. Lab. Syst.* 2010, 100, 28–35. [CrossRef]
19. Laref, R.A.; Lossen, S.; Siadat, M. Orthogonal Signal Correction to Improve Stability Regression Model in Gas Sensor Systems. *J. Sens.* 2017, 1–8. [CrossRef]
20. Aliaghasarghamish, M.; Ebrahimi, S. Recursive least squares fuzzy modeling of chemoresistive gas sensors for drift compensation. In Proceedings of the 2011 International Symposium on Innovations in Intelligent Systems and Applications, Istanbul, Turkey, 15–18 June 2011; pp. 1–5.
21. Zhang, L.; Liu, Y.; He, Z.; Liu, J.; Deng, P.; Zhou, X. Anti-drift in E-nose: A subspace projection approach with drift reduction. *Sens. Actuators B Chem.* 2017, 253, 407–417. [CrossRef]
22. Zuppa, M.; Distante, C.; Siciliano, P.; Persaud, K.C. Drift counteraction with multiple self-organising maps for an electronic nose. *Sens. Actuators B Chem.* 2004, 98, 303–317. [CrossRef]
23. Licen, S.; Barbieri, G.; Fabbri, A.; Brigguglio, S.C.; Pillon, A.; Stel, F.; Barbieri, P. Odor control map: Self organizing map built from electronic nose signals and integrated by different instrumental and sensorial data to obtain an assessment tool for real environmental scenarios. *Sens. Actuators B Chem.* 2018, 263, 476–485. [CrossRef]
24. Distante, C.; Siciliano, P.; Vasanelli, L. Odor discrimination using adaptive resonance theory. *Sens. Actuators B Chem.* 2000, 69, 248–252. [CrossRef]
25. Kadri, C.T.; Zhang, L. Neural Network Ensembles for Online Gas Concentration Estimation Using an Electronic Nose. Int. J. Comput. Sci. 2013, 10, 129–135.

26. Martinek, E.; Magna, G.; De Vito, S.; Di Fuccio, R.; Di Francia, G.; Vergara, A.; Di Natale, C. An adaptive classification model based on the Artificial Immune System for chemical sensor drift mitigation. Sens. Actuators B Chem. 2013, 177, 1017–1026. [CrossRef]

27. Feng, L. Gas identification with drift counteraction for electronic noses using augmented convolutional neural network. Sens. Actuators B Chem. 2022, 351, 130986. [CrossRef]

28. Gordon, S.M.; Szidon, J.P.; Krotoszynski, B.K.; Gibbons, R.D.; O’Neill, H.J. Volatile organic compounds in exhaled air from patients with lung cancer. Clin. Chem. 1985, 31, 1278–1282. [CrossRef] [PubMed]

29. de Meij, T.G.; Larbi, I.B.; van der Schee, M.P.; Lentferink, Y.E.; Paff, T.; Terhaar Sive Droste, J.S.; Mulder, C.J.; van Bodegraven, A.A.; de Boer, N.K. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: Proof of principle study. Int. J. Cancer 2014, 134, 1132–1138. [CrossRef] [PubMed]

30. Arasaradnam, R.P.; Westenbrink, E.; McFarlane, M.J.; Harbord, R.; Chambers, S.; O’Connell, N.; Bailey, C.; Nwokolo, C.U.; Bardhan, K.D.; Savage, R.; et al. Differentiating coeliac disease from irritable bowel syndrome by urinary volatile organic compound analysis—a pilot study. PLoS ONE 2014, 9, e107312. [CrossRef] [PubMed]

31. de Meij, T.G.; de Boer, N.K.; Benninga, M.A.; Lentferink, Y.E.; de Grooth, T.; van de Velde, M.E.; van Bodegraven, A.A.; van der Schee, M.P. Faecal gas analysis by electronic nose as novel, non-invasive method for assessment of active and quiescent paediatric inflammatory bowel disease: Proof of principle study. J. Crohn’s Colitis 2014, 6, 111–113. [CrossRef]

32. van Gaal, N.; Lakenman, R.; Covington, J.; Savage, R.; de Grooth, E.; Bomers, M.; Benninga, M.; Mulder, C.; de Boer, N.; de Meij, T. Faecal volatile organic compounds analysis using field asymmetric ion mobility spectrometry: Non-invasive diagnostics in paediatric inflammatory bowel disease. J. Breath Res. 2017, 12, 016006. [CrossRef]

33. Ahmed, I.; Greenwood, R.; Costello, B.; Ratcliffe, N.; Probert, C.S. Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2016, 43, 596–611. [CrossRef] [PubMed]

34. Bodelier, A.G.; Smolinska, A.; Baranska, A.; Dallinga, J.W.; Mujagic, Z.; Vanhees, K.; van den Heuvel, T.; Masclee, A.A.; Jonkers, D.; Pierik, M.J.; et al. Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohn’s Disease: A Metabolomic Approach. Inflamm. Bowel Dis. 2015, 21, 1776–1785. [CrossRef] [PubMed]

35. Arasaradnam, R.P.; McFarlane, M.; Daulton, E.; Skinner, J.; O’Connell, N.; Wurie, S.; Chambers, S.; Nwokolo, C.; Bardhan, K.; Savage, R.; et al. Non-invasive exhaled volatile biomarker analysis to detect inflammatory bowel disease (IBD). Dig. Liver Dis. 2016, 48, 148–153. [CrossRef]

36. Bosch, S.; Lemmen, J.P.M.; de Menezes, R.X.; van der Hulst, R.; Kuijvenhoven, J.; Stokkers, P.C.F.; de Meij, T.G.J.; de Boer, N. The influence of lifestyle factors on faecal volatile organic compound composition as measured by an electronic nose. J. Breath Res. 2019, 13, 046001. [CrossRef] [PubMed]

37. Satsangi, J.; Silverberg, M.S.; Vermeire, S.; Colombel, J.F. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 2006, 55, 749–753. [CrossRef]

38. Verschuren, E.C.; van den Eertwegh, A.J.; Wonders, J.; Slangen, R.M.; van Delft, F.; van Bodegraven, A.; Neefjes-Borst, A.; de Boer, N.K. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis. Clin. Gastroenterol. Hepatol. 2016, 14, 836–842. [CrossRef]

39. Lewis, J.D.; ChuaI, S.; Nessel, L.; Lichtenstein, G.R.; Aberra, F.N.; Ellenberg, J.H. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm. Bowel Dis. 2008, 14, 1660–1666. [CrossRef] [PubMed]

40. Rutgeerts, P.; Geboes, K.; vantrappen, G.; Beyls, J.; Kerremans, R.; Hiele, M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990, 99, 956–963. [CrossRef]

41. Bosch, S.; El Manouni El Hassani, S.; Covington, J.; Wicaksono, A.N.; Bomers, M.K.; Benninga, M.A.; Mulder, C.J.J.; de Boer, N.K.H.; de Meij, T.G. Optimized Sampling Conditions for Fecal Volatile Organic Compound Analysis by Means of Field Asymmetric Ion Mobility Spectrometry. Anal. Chem. 2018, 90, 7972–7981. [CrossRef]

42. Berkhourt, D.J.; Benninga, M.A.; van Stein, R.M.; Brinkman, P.; Niemarkt, H.J.; de Boer, N.K.; de Meij, T.G. Effects of Sampling Conditions and Environmental Factors on Fecal Volatile Organic Compound Analysis by an Electronic Nose Device. Sensors 2016, 16, 1967. [CrossRef] [PubMed]